|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US6685941B1
(en)
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
DE69233186T2
(de)
|
1991-05-06 |
2004-06-03 |
The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer |
Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
ES2123001T5
(es)
|
1991-06-27 |
2009-04-16 |
Bristol-Myers Squibb Company |
Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
PT752248E
(pt)
|
1992-11-13 |
2001-01-31 |
Idec Pharma Corp |
Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
US6482919B2
(en)
|
1993-02-01 |
2002-11-19 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
WO1996009380A1
(en)
|
1994-09-23 |
1996-03-28 |
The University Of British Columbia |
Method of enhancing expression of mhc class i molecules bearing endogenous peptides
|
|
DE69519521T2
(de)
|
1994-10-03 |
2001-06-28 |
The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
DK1068241T3
(da)
|
1998-04-02 |
2008-02-04 |
Genentech Inc |
Antistofvarianter og fragmenter deraf
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
DK2272859T3
(en)
|
1998-08-07 |
2015-01-19 |
Univ Washington |
Immunological herpes simplex virus antigens and methods for their use
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
|
ES2308989T3
(es)
|
1999-08-09 |
2008-12-16 |
Targeted Genetics Corporation |
Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
|
|
WO2001021796A2
(en)
|
1999-09-21 |
2001-03-29 |
Genetics Institute, Inc. |
Gl50 molecules and uses therefor
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
CA2395945C
(en)
|
2000-01-03 |
2013-12-24 |
Tr Associates, L.L.C. |
Novel chimeric proteins and methods for using the same
|
|
JP4921669B2
(ja)
|
2000-01-21 |
2012-04-25 |
バイオヴェックス リミテッド |
ウイルス株
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
UA87432C2
(uk)
*
|
2000-05-26 |
2009-07-27 |
Бристол-Майерс Сквибб Компани |
Розчинний мутантний ctla4 та його застосування
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
AU2001272978A1
(en)
|
2000-06-23 |
2002-01-08 |
Maxygen, Inc. |
Novel co-stimulatory molecules
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
PL212205B1
(pl)
|
2000-07-03 |
2012-08-31 |
Bristol Myers Squibb Co |
Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
PL204899B1
(pl)
|
2001-05-23 |
2010-02-26 |
Bristol Myers Squibb Co |
Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
US6871421B2
(en)
|
2001-09-21 |
2005-03-29 |
Daniel R. Potter |
Footwear with bladder type stabilizer
|
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
US7247615B2
(en)
|
2001-11-30 |
2007-07-24 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Peptide agonists of prostate-specific antigen and uses therefor
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
AR042485A1
(es)
|
2002-12-16 |
2005-06-22 |
Genentech Inc |
Anticuerpo humanizado que se une al cd20 humano
|
|
SI1576182T2
(sl)
|
2002-12-23 |
2020-07-31 |
Bristol-Myers Squibb Company |
Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev
|
|
WO2004072286A1
(ja)
|
2003-01-23 |
2004-08-26 |
Ono Pharmaceutical Co., Ltd. |
ヒトｐｄ−１に対し特異性を有する物質
|
|
EP2028270B9
(en)
|
2003-06-18 |
2012-04-25 |
Genelux Corporation |
Modified recombinant vaccinia viruses, uses thereof
|
|
CA2762015A1
(en)
|
2003-08-04 |
2005-02-24 |
Bristol-Myers Squibb Company |
Methods for treating cardiovascular disease using a soluble ctla4 molecule
|
|
EP2275448A3
(en)
|
2003-12-19 |
2013-02-06 |
Genentech, Inc. |
Monovalent antibody fragments useful as therapeutics
|
|
CA2885854C
(en)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
|
DK2471813T3
(en)
|
2004-07-15 |
2015-03-02 |
Xencor Inc |
Optimized Fc variants
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
EP1810979B1
(en)
|
2004-09-22 |
2012-06-20 |
Kyowa Hakko Kirin Co., Ltd. |
STABILIZED HUMAN IgG4 ANTIBODIES
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
US20090208924A1
(en)
|
2004-12-01 |
2009-08-20 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of Replication Competent Viruses for Therapeutic Use
|
|
US20080181888A1
(en)
|
2004-12-31 |
2008-07-31 |
Ambrose Christine M |
Polypeptides That Bind Br3 and Uses Thereof
|
|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
|
EA013122B1
(ru)
|
2005-04-06 |
2010-02-26 |
Бристол-Маерс Сквибб Компани |
Способы лечения иммунных нарушений, связанных с пересадкой трансплантата, растворимым мутантным ctla4
|
|
JP2007103345A
(ja)
|
2005-09-07 |
2007-04-19 |
Toyota Motor Corp |
チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法
|
|
EP1960525B1
(en)
|
2005-09-09 |
2013-04-24 |
Zymogenetics, Inc. |
Method for preparing trimeric proteins
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
JP5096369B2
(ja)
|
2005-12-20 |
2012-12-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
組成物および組成物の製造方法
|
|
WO2008100292A2
(en)
|
2006-10-16 |
2008-08-21 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
DK2856876T3
(en)
|
2007-03-30 |
2018-04-03 |
Memorial Sloan Kettering Cancer Center |
Constitutive expression of co-stimulatory ligands on adoptively transmitted T lymphocytes
|
|
US20090117034A1
(en)
|
2007-06-15 |
2009-05-07 |
Nanhai Chen |
Microorganisms for imaging and/or treatment of tumors
|
|
JP2010533649A
(ja)
|
2007-07-13 |
2010-10-28 |
ザ ジョンズ ホプキンス ユニバーシティー |
Ｂ７−ｄｃ改変体
|
|
US20090162288A1
(en)
|
2007-07-18 |
2009-06-25 |
Nanhai Chen |
Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
RU2506275C2
(ru)
|
2007-11-01 |
2014-02-10 |
Астеллас Фарма Инк. |
Иммуносупрессорные полипептиды и нуклеиновые кислоты
|
|
CN101925612A
(zh)
|
2007-11-27 |
2010-12-22 |
维文蒂阿生物技术公司 |
针对癌相关的nfkbib变体的表位的抗体及其用途
|
|
TR201802323T4
(tr)
|
2007-12-11 |
2018-03-21 |
Univ North Carolina Chapel Hill |
Polipürin yolu modifiye edilmiş retroviral vektörler.
|
|
JP5770624B2
(ja)
|
2008-04-09 |
2015-08-26 |
ジェネンテック， インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
|
US7915222B2
(en)
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
|
EP2300023A2
(en)
|
2008-05-16 |
2011-03-30 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
US9283184B2
(en)
|
2008-11-24 |
2016-03-15 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
CA2751489A1
(en)
|
2009-02-04 |
2010-08-12 |
Board Of Regents, The University Of Texas System |
Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
|
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
CN104826106B
(zh)
|
2009-09-30 |
2019-01-11 |
斯隆凯特林防癌纪念中心 |
用于治疗癌症的组合免疫疗法
|
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
ES2724451T3
(es)
|
2010-02-04 |
2019-09-11 |
Univ Pennsylvania |
ICOS regula fundamentalmente la expansión y la función de linfocitos Th17 humanos inflamatorios
|
|
LT3053932T
(lt)
*
|
2010-02-19 |
2020-11-10 |
Xencor, Inc. |
Nauji ctla4-ig imunoadhezinai
|
|
PL2542590T5
(pl)
*
|
2010-03-05 |
2020-08-10 |
The Johns Hopkins University |
Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
|
|
US8642557B2
(en)
|
2010-03-12 |
2014-02-04 |
Abbvie Biotherapeutics Inc. |
CTLA4 proteins and their uses
|
|
KR101860963B1
(ko)
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CA3179835A1
(en)
|
2011-01-18 |
2012-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
|
JP5972915B2
(ja)
|
2011-03-16 |
2016-08-17 |
アムジエン・インコーポレーテツド |
Ｆｃ変異体
|
|
EP3632463A1
(en)
|
2011-04-08 |
2020-04-08 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
TWI496886B
(zh)
|
2011-06-24 |
2015-08-21 |
Taipei Veteran General Hospital |
提升感染性與惡性疾病之治療之免疫反應
|
|
EP3357511B1
(en)
|
2011-06-30 |
2020-05-13 |
Genzyme Corporation |
Inhibitors of t-cell activation
|
|
EA201490636A1
(ru)
|
2011-09-16 |
2014-08-29 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
|
|
WO2013041029A1
(en)
|
2011-09-23 |
2013-03-28 |
Igenimed Pharmaceuticals Inc. |
Novel soluble ctla4 variants
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
CA3179537A1
(en)
|
2012-02-27 |
2013-09-06 |
Amunix Pharmaceuticals, Inc. |
Xten conjugate compositions and methods of making same
|
|
US9758566B2
(en)
|
2012-03-29 |
2017-09-12 |
The General Hospital Corporation |
Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
|
|
JP6228971B2
(ja)
*
|
2012-05-11 |
2017-11-08 |
メディミューン，エルエルシー |
Ｃｔｌａ−４バリアント
|
|
US20130319861A1
(en)
|
2012-05-30 |
2013-12-05 |
Berkeley Lights, Inc. |
Outputting A Droplet Of Liquid Medium From A Device For Processing Micro-Objects In The Medium
|
|
KR20150018604A
(ko)
|
2012-06-06 |
2015-02-23 |
온코메드 파마슈티칼스, 인크. |
히포 경로를 조절하는 결합제 및 그의 용도
|
|
KR20150033703A
(ko)
|
2012-06-27 |
2015-04-01 |
오르반 바이오테크 엘엘씨 |
당뇨병 치료를 위한 ctla4 융합 단백질
|
|
JP5857896B2
(ja)
|
2012-07-06 |
2016-02-10 |
東京エレクトロン株式会社 |
成膜装置の運転方法及び成膜装置
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
CA2892831A1
(en)
|
2012-12-04 |
2014-06-12 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
US9944689B2
(en)
|
2013-03-07 |
2018-04-17 |
The General Hospital Corporation |
Human CTLA4 mutants and use thereof
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
HK1219740A1
(zh)
|
2013-03-15 |
2017-04-13 |
Biogen Ma Inc. |
使用抗αVβ5抗体治疗和预防急性肾损伤
|
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
|
WO2014207748A1
(en)
|
2013-06-27 |
2014-12-31 |
Alexander Biro |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
SG11201600310QA
(en)
|
2013-07-16 |
2016-02-26 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
|
EP3835318B1
(en)
|
2014-01-15 |
2025-10-29 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
EP3101035B1
(en)
|
2014-01-28 |
2021-10-06 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Bifunctional fusion protein, preparation method therefor, and use thereof
|
|
ES2792849T3
(es)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
|
|
AU2015249656A1
(en)
|
2014-04-25 |
2016-11-03 |
Bristol-Myers Squibb Company |
Use of CTLA4 compound for achieving drug-free remission in subjects with early RA
|
|
WO2015172305A1
(zh)
|
2014-05-12 |
2015-11-19 |
上海康岱生物医药技术股份有限公司 |
抑制taci-baff复合物形成的融合蛋白及其制法和用途
|
|
KR20150135148A
(ko)
*
|
2014-05-23 |
2015-12-02 |
주식회사 제넥신 |
Pd-l1 융합 단백질 및 이의 용도
|
|
CA2955015A1
(en)
|
2014-07-15 |
2016-01-21 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
|
SG10201811841UA
(en)
|
2014-07-16 |
2019-02-27 |
Genentech Inc |
Methods of treating cancer using tigit inhibitors and anti-cancer agents
|
|
ES2909957T3
(es)
|
2014-07-16 |
2022-05-11 |
Transgene |
Virus oncolítico para la expresión de moduladores de puntos de control inmunitarios
|
|
HRP20201153T1
(hr)
|
2014-08-08 |
2021-01-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Pd-1 sredstva visokog afiniteta i načini uporabe
|
|
SG11201701506PA
(en)
|
2014-09-03 |
2017-03-30 |
Bavarian Nordic As |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
CN107207597A
(zh)
|
2014-11-06 |
2017-09-26 |
儿研所儿童医学中心 |
用于癌症和自身免疫疾病的免疫疗法
|
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
CN107708725A
(zh)
|
2015-04-02 |
2018-02-16 |
坎库雷有限公司 |
用于引发免疫应答的剂和组合物
|
|
PT3283508T
(pt)
|
2015-04-17 |
2021-06-21 |
Alpine Immune Sciences Inc |
Proteínas imuno modulatórias com afinidades afináveis
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
SI3328419T1
(sl)
|
2015-07-30 |
2021-11-30 |
Macrogenics, Inc. |
PD-1-vezavne molekule in postopki uporabe le-teh
|
|
CA2993478A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
|
MX2018003144A
(es)
|
2015-09-14 |
2018-09-11 |
Alpine Immune Sciences Inc |
Dominios de superfamilia de inmunoglobulina de variante ajustable y terapia con células genéticamente modificadas.
|
|
TWI705972B
(zh)
*
|
2015-11-04 |
2020-10-01 |
臺北榮民總醫院 |
惡性病變的組合治療
|
|
AU2016370376B2
(en)
|
2015-12-14 |
2023-12-14 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
IL262366B2
(en)
|
2016-04-15 |
2024-07-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins and CD80 variants and their uses
|
|
AU2017250358B2
(en)
|
2016-04-15 |
2023-06-01 |
Alpine Immune Sciences, Inc. |
ICOS ligand variant immunomodulatory proteins and uses thereof
|
|
CN109689096A
(zh)
|
2016-05-18 |
2019-04-26 |
阿尔伯特爱因斯坦医学院公司 |
变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
MA46534A
(fr)
|
2016-10-14 |
2019-08-21 |
Xencor Inc |
Protéines de fusion fc hétérodimères il15/il15r
|
|
SG11201903407XA
(en)
|
2016-10-20 |
2019-05-30 |
Alpine Immune Sciences Inc |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
HUE064136T2
(hu)
|
2017-03-16 |
2024-02-28 |
Alpine Immune Sciences Inc |
PD-L1 variáns immunmódosító fehérjék és alkalmazásuk
|
|
KR20250083578A
(ko)
|
2017-03-16 |
2025-06-10 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd80 변이체 면역조절 단백질 및 그의 용도
|
|
US11732022B2
(en)
|
2017-03-16 |
2023-08-22 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
|
CA3077509A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
IL320945A
(en)
|
2017-10-18 |
2025-07-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins, ligands for ICOs, and compositions and methods related thereto
|
|
AU2019205273B2
(en)
|
2018-01-03 |
2024-04-04 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
WO2020047329A1
(en)
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
|
AU2019389151B2
(en)
|
2018-11-30 |
2025-07-24 |
Alpine Immune Sciences, Inc. |
CD86 variant immunomodulatory proteins and uses thereof
|
|
PE20230494A1
(es)
|
2020-05-08 |
2023-03-23 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas
|